CBLPath Revenue and Competitors

Port Chester, NY USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CBLPath's estimated annual revenue is currently $34.8M per year.(i)
  • CBLPath's estimated revenue per employee is $292,689

Employee Data

  • CBLPath has 119 Employees.(i)
  • CBLPath grew their employee count by -2% last year.

CBLPath's People

NameTitleEmail/Phone
1
VP FinanceReveal Email/Phone
2
VP Quality Assurance, Regulatory and ComplianceReveal Email/Phone
3
Director DermatopathologyReveal Email/Phone
4
Director Breast Pathology at CBLPathReveal Email/Phone
5
Director Accounts ReceivableReveal Email/Phone
6
Lab Operations Manager - Post TechnicalReveal Email/Phone
7
ManagerReveal Email/Phone
8
Manager, Client ServiceReveal Email/Phone
9
Breast PathologistReveal Email/Phone
10
FISH Cytomolecular TechnologistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$49.9M17210%N/AN/A
#2
$300.1M794-9%N/AN/A
#3
$10.2M440%N/AN/A
#4
$23.5M855%N/AN/A
#5
$30.5M14234%N/AN/A
#6
$31.9M1189%N/AN/A
#7
$26.5M998%N/AN/A
#8
$4.9M2921%N/AN/A
#9
$75.7M232-3%N/AN/A
#10
$229.4M6693%$177.7MN/A
Add Company

What Is CBLPath?

CBLPath, Inc. is a leading provider of sub-specialized anatomic pathology and molecular diagnostic laboratory services. We are committed to partnering with our physician-clients to provide the best possible patient care. Founded in 1988 as Cytopath Biopsy Lab, our landmark laboratory quickly established a reputation for providing definitive diagnoses coupled with extraordinary customer service.

keywords:N/A

N/A

Total Funding

119

Number of Employees

$34.8M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CBLPath News

2022-03-22 - After living near Chernobyl, these Pitt researchers set their ...

UPMC licensed ThyroSeq from the University in 2017 and partnered with CBLPath, Inc., a branch of the Austin, Texas-based Sonic Healthcare...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$31.1M1322%N/A
#2
$49.5M2101%N/A
#3
$30.1M22350%N/A
#4
$66.2M237N/AN/A
#5
$69.8M2592%N/A